Seeking Alpha

KarinCA

 
View as an RSS Feed
View KarinCA's Comments BY TICKER:
Latest  |  Highest rated
  • T2 Biosystems: Soon To Be The New Leader In Candida Related Sepsis Diagnosis [View article]
    Good article on $TTOO...It's an interesting company. thanks...
    Dec 17, 2014. 11:26 PM | Likes Like |Link to Comment
  • 4 Companies To Look At After WHO Ebola Consultation In Geneva [View article]
    $BCRX - http://seekingalpha.co...
    Dec 15, 2014. 12:51 PM | 1 Like Like |Link to Comment
  • Ebola Treated With GlaxoSmithKline Subsidiary HIV Product [View article]
    $GSK - Ebola vaccine from Glaxo passes early safety test
    http://yhoo.it/1usAxvW
    Dec 11, 2014. 02:11 PM | 2 Likes Like |Link to Comment
  • 4 Companies To Look At After WHO Ebola Consultation In Geneva [View article]
    $NLNK - Ebola vaccine trial halted temporarily after joint pains: Geneva hospital
    http://yhoo.it/1DhYuPN

    $GSK - Ebola vaccine from Glaxo passes early safety test
    http://yhoo.it/1usAxvW
    Dec 11, 2014. 02:07 PM | 1 Like Like |Link to Comment
  • Update: Cellceutix Calls Out To President Obama About Brilacidin [View article]
    Cellceutix CEO: Cubist acquisition made us look like 'absolute geniuses'
    http://bit.ly/1z7z9Tt

    lol... can't say the man is shy.
    Dec 10, 2014. 03:34 PM | 1 Like Like |Link to Comment
  • Interview With Leo Ehrlich, Cellceutix CEO Following Acquisition Of PolyMedix Assets [View article]
    CEO of CTIX did better buying the PolyMedix assets out of bk court than MRK did buying CBST. Brilacidin single day of treatment is looking better than Cubicn.
    Dec 10, 2014. 03:32 PM | 1 Like Like |Link to Comment
  • Update: Cellceutix Calls Out To President Obama About Brilacidin [View article]
    Hope4Future... Bioequivalence of Prurisol with Avacavir Sulfate was needed for the FDA to allow use of the 505(b)(2) regulatory pathway. The 505(b)(2) pathway is much quicker than the 505(b)(1) pathway since the long term safety data already exists.

    Following is an interesting summary of the 505(b)(2) pathway by Kenneth Phelps:

    Taking the 505(b)(2) Route by KENNETH V. PHELPS, PRESIDENT AND CEO; CAMARGO PHARMACEUTICAL SERVICES, CINCINNATI

    http://bit.ly/1qwyNFB

    Quote “Drugs approved under 505(b)(2), on the other hand, can rely in part on data from existing reference drugs. This means they can be developed and achieve FDA approval in as little as 30 months with only a fraction of the number of required clinical trials and at much lower cost. Additionally, unlike generic drugs approved under Section 505(j), where exclusivity can be held for only 180 days, the 505(b)(2) applicant may qualify for three, five, or seven years of market exclusivity, depending on the extent of the change to the previously approved drug and the type of clinical data included in the New Drug Application (NDA). “
    Dec 10, 2014. 02:23 PM | 1 Like Like |Link to Comment
  • Many Sharp Minds Are Invested Long In Tekmira [View article]
    For those wanting to know where $TKMR stands with WHO on the list of Ebola treatments: http://bit.ly/1zMKgRe

    Do searches for TKM and Tekmira. 1.1 Lead experimental therapies on Pg 6 is interesting. TKM is close to the top. We may yet get another Ebola related pop once those doses are ready for delivery. Or not.... But, thought some might find this interesting.
    Dec 9, 2014. 11:15 PM | 1 Like Like |Link to Comment
  • Update: Cellceutix Calls Out To President Obama About Brilacidin [View article]
    buyitcheap... As Leo has stated. The best is yet to come. ;)

    Watch this link for additional trials in the near future.
    http://1.usa.gov/1z3ToBI
    Dec 9, 2014. 05:55 PM | 1 Like Like |Link to Comment
  • Many Sharp Minds Are Invested Long In Tekmira [View article]
    Zeypo... only you can answer that. It's up a bit from the low. Hopefully, it continues.
    Dec 9, 2014. 01:35 PM | 1 Like Like |Link to Comment
  • Did The Medicines Company Trump Cellceutix And Others In A $1B-Plus Skin Infection Market? [View article]
    Matija Snuderl and Jim Bowie... Biotech investing requires patience and a lot of research to invest. No doubt about it. ;)

    There's always risk, but, CTIX is looking good. Especially, with the upcoming catalysts.
    Dec 8, 2014. 04:39 PM | 1 Like Like |Link to Comment
  • Regulatory Support Creates Opportunity For Antibiotic Makers Otonomy And Cellceutix [View article]
    $CTIX Cellceutix Antibiotic Brilacidin Receives QIDP Designation From FDA

    http://bit.ly/1ytz92j
    Dec 8, 2014. 12:08 PM | 2 Likes Like |Link to Comment
  • Update: Cellceutix Calls Out To President Obama About Brilacidin [View article]
    $CTIX - Cellceutix Antibiotic Brilacidin Receives QIDP Designation From FDA
    http://bit.ly/1ytz92j
    Dec 8, 2014. 12:06 PM | 1 Like Like |Link to Comment
  • Many Sharp Minds Are Invested Long In Tekmira [View article]
    I view all of biotech with a long term view. I've been watching this one closely since 5/13/10 when I created the following board on ihub: http://bit.ly/1vXF2mh

    Long term, I still view this one as going up. Btw, most of the posts on the above linked board are nonsense from the time TKMR hit the news with their Ebola work.

    The DoD has ordered doses for testing. TKMR is supposed have some ready for delivery this month. In the meantime, their drug isn't one of the two experimental cures being tested by Medicins San Frontieres. They are currently testing Brincidofovir and Favipiravir. Traders that got into TKMR due to Ebola may be dumping and causing this volatility since TKMR isn't in the news at the moment. The rest of the pipeline is forgotten by most.

    Whatever, the reason, it's volatile.
    Dec 5, 2014. 02:03 PM | 1 Like Like |Link to Comment
  • Many Sharp Minds Are Invested Long In Tekmira [View article]
    The reaction to the S-3 filing for $150,000,000 surprises me. It's replacing a Form F-10 filed in February 2014 for $60,562,500. It's only adding $89,437,500. The additional $89mil at $16 per share is only an additional 5.589 mil shares. At $13 per share it's still only 6.879 mil more shares.

    Having the shelf sitting there for when they need capital puts them in a stronger position to move the pipeline forward. The $140mil from the US DoD covers the Ebola program.

    S-3 http://1.usa.gov/1tOa9v2
    "USE OF PROCEEDS
    Unless otherwise specified in a prospectus supplement, the net proceeds that we receive from the sale of our common shares will be used for working capital and general corporate purposes, including, but not limited to, progressing our research and development programs, supporting our clinical programs and manufacturing activities, and advancing and protecting our LNP technology."

    Sedar filings: http://bit.ly/1tOaazi

    TKMR pipeline: http://bit.ly/1tOa9v7
    Dec 3, 2014. 05:12 PM | 2 Likes Like |Link to Comment
COMMENTS STATS
372 Comments
560 Likes